Lynthera is a technology company focused on the research and development of novel therapy to improve the treatment of eye disease. The company has developed a Drug Delivery Contact Lens (DDCL) that employs nanotechnology to achieve significant advantages over topical eye drops. Currently in development to treat glaucoma, this platform has the potential to create a new paradigm of drug delivery that transforms the broader field of eye care.